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ABSTRACT
Introduction: Although liraglutide is widely
recognized to have glycemic and extra-glycemic
effects, few studies have compared these effects
in relation to hypoglycemic treatment starting
from the diagnosis of diabetes. We evaluated
the effectiveness of liraglutide in reducing the
Framingham risk score (FRS) and visceral adi-
posity index (VAI) in relation to first-line
hypoglycemic treatment from diagnosis of type
2 diabetes, continued without any changes.
Methods: We selected 105 diabetic outpatients
who were treated with liraglutide for at least
48 months as an add-on therapy to metformin
alone (group A, n = 52) or insulin secretagogues
(group B, n = 53) from diagnosis time.
Results: Although both groups showed a
reduction in BMI, waist circumference, blood
pressure, HbA1c and triglycerides, only group A
showed a significant reduction in FRS
(p\0.001) and VAI (p = 0.012) after 48 months.
No significant intergroup difference was found
for any parameters at either baseline or
48 months, with the exception of FRS at
48 months, lower in group A (p = 0.002),
regardless of duration of disease, improvement
in glycemic control and VAI.
Conclusion: Our data show that during a
48-month follow-up liraglutide was more effi-
cacious in reducing cardiovascular risk than
when it was used as add-on therapy to the
first-line therapy from diagnosis with met-
formin and not with insulin secretagogues.
Keywords: Cardiovascular risk; Diabetes;
Liraglutide; Visceral adiposity
INTRODUCTION
Liraglutide is effective in the treatment of
type 2 diabetes, showing both glycemic and
extra-glycemic effects, thereby achieving many
of the goals of ideal antihyperglycemic therapy
[1]. The main effect is certainly a significant
weight reduction, which seems to be indepen-
dent of glycemic improvement [2].
In addition, a reduction of cardiovascular
(CV) risk was confirmed by large randomized
trials [3], and the beneficial effect of liraglutide
on visceral fat adiposity was clearly demon-
strated [4]. The visceral adiposity index (VAI), a
valuable indicator of visceral adipose function
and insulin sensitivity, has been demonstrated
to be an independent predictor of CV diseases
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and an easy tool for mirroring a condition of
cardiometabolic (CM) risk [5].
This study aimed to evaluate the effective-
ness of liraglutide in a real-world setting in
reducing a composite index of CV risk [the
Framingham risk score (FRS)] [4] and VAI in
relation to first-line hypoglycemic treatment
from the time of diagnosis of diabetes, which
never changed during the entire period before
liraglutide addition.
METHODS
In this retrospective study, we extracted data of
395 diabetic outpatients who were given
liraglutide with at least 48 months of follow-up.
Specifically, we carefully selected data of 135
patients who were treated with just one oral
hypoglycemic agent continuously from diag-
nosis, excluding those whose therapy was
modified even for a brief period. Before the
48-month observational period, no patient
enrolled needed to have the hypoglycemic
therapy modified on the basis of glycemic con-
trol (HbA1c levels), and there was good adher-
ence until the last observation. During the
48 months of follow-up, any change in con-
comitant medications was considered an
exclusion criterion. Specifically, 30 patients
with a comparable number (14 in group A and
16 in group B) were excluded from the analysis
(respectively 12 at 12 months, 6 at 24 months, 9
at 36 months and 3 at 48 months) because of
discontinuation of liraglutide, a change in
concomitant medications (9.6%), low compli-
ance with treatment (8.8%) or lack of follow-up
(3.7%).
The final analysis comprised 105 patients,
subdivided into group A [52 patients, mean age
55 ± 8 years, treated with liraglutide as an
add-on therapy to metformin (MET)] and group
B [53 patients, mean age 58 ± 9 years, treated
with liraglutide on as an add-on to insulin sec-
retagogues (SE)]. Due to the retrospective nature
of the study and for the purpose of including all
the patients who met the inclusion criteria
expressed above, a priori power calculation was
not performed.
In most cases, SE as first-line treatment was
autonomously prescribed by primary care
physicians of patients or as a result ofMET severe
gastric intolerance after the first 2–3 days and
immediately suspended by patient’s decision.
The FRS for estimating the 10-year risk for
CV events was calculated on the basis of age,
sex, total and HDL cholesterol, blood pressure
and smoking status [6].
The VAI was calculated as described [5],
using the following formulas:
Males: VAI ¼ ½waist circumference=39:68
þ ð1:88 body mass indexÞ
 ðtriglycerides=1:03Þ
 ð1:31=HDL cholesterolÞ
Females: VAI ¼ ½waist circumference=36:58
þ ð1:89 body mass indexÞ
 ðtriglycerides=0:81Þ
 ð1:52=HDL cholesterolÞ:
All procedures were in accordance with the
ethical standards of the responsible committee
on human experimentation (institutional and
national) and with the Helsinki Declaration of
1964, as revised in 2013. Approval was obtained
from the Ethic Committee of the University of
Palermo. At the time of hospitalization, an
informed consent for the scientific use of the
data was obtained from all patients for being
included in the study.
Statistical Analysis
The SPSS version 19 (SPSS, Inc.) was used for
data analysis. Data were presented as
mean ± SD or rates and proportions. The
normality of distribution of the quantitative
variables was assessed using the Kol-
mogorov-Smirnov test. The differences between
the two groups were evaluated with t-Student
for quantitative variables and v2 for trend for
categorical variables. A p value\0.05 was con-
sidered statistically significant.
The statistical significance of the results was
also confirmed through the data analysis of the
‘‘last observation carried forward’’ (LOCF) in the
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initial cohort of 135 patients, also including the
latest clinical and biochemical data available at
the last observation, corresponding to the time
of exclusion from the study, of the 30 patients
excluded from the final analysis.
RESULTS
Patients in group A and B were matched for
duration of diabetes (7.5 ± 5.4 vs.
8.6 ± 5.2 years; p = 0.305), prevalence of hyper-
tension (42% vs. 43%; p = 0.579), smoking status
(38.4% vs. 26.4%; p = 0.133), previous CV events
(17.3% vs. 16.9%; p = 0.584), and use of anti-
platelet therapy (26% vs. 30%; p = 0.315) or
statins (27% vs. 20%; p = 0.103). Eighty-one
percent of patients were taking antihypertensive
drugs (angiotensin type 1 receptor blockers in 49
patients, angiotensin-converting enzyme inhi-
bitors in 33 patients, calcium entry blockers in
16 patients, diuretics in 36 patients, beta-block-
ers in 30 patients), 53% aspirin and 44% statins,
without any difference between the two groups.
The mean dose of MET administered to patients
in group A was 1.5–2.0 g daily. In group B, 25
(47%) patients were taking repaglinide (3.0–4.0 g
daily), 20 (38%) gliclazide (240 mg daily) and 8
(15%) glimepiride (4.0 mg daily). Liraglutide was
administered at the dose of 1.2 mg during the
entire follow-up.
After addition of liraglutide, after 48 months
all patients showed a significant reduction in
body mass index (p\0.001 in both groups),
waist circumference (p\0.001 in both groups),
systolic (p\0.001 in group A; p = 0.005 in
group B) and diastolic blood pressure (p\0.001
in group A; p = 0.007 in group B), HbA1c
(p\0.001 in both groups) and triglycerides
(p\0.001 in group A; p = 0.002 in group B),
without any significant change in HDL and LDL
cholesterol (Table 1).
In the whole population, the FRS showed a
significant reduction from baseline to
48 months (p = 0.002), while, subdividing
patients into the two groups, this result was
confirmed in group A (p\0.001) but not in
group B (p = 0.077). Similarly, the VAI showed a
significant reduction in the whole population
(p = 0.002) and in group A (p = 0.012), but not
in group B (p = 0.058) (Fig. 1). At 48 months,
group A showed a lower FRS (p = 0.002) and a
higher change in FRS from baseline to
48 months (p\0.001) than group B, without
any difference in other parameters (Table 1).
At multivariate analysis, concomitant hypo-
glycemic therapy proved to be the only variable
independently associated with both FRS at
48 months (b 0.303; 95% CI 1.480–5.880;
p = 0.001) and the change in FRS from baseline
to 48 months (b 0.424; 95% CI 0.239–0.601;
p\0.001) (Table 2).
The statistical significance of these results
was also confirmed when we performed the
LOCF data analysis in the initial cohort of 135
patients (data not shown). No serious adverse or
CV events were observed during the follow-up.
DISCUSSION
This study demonstrates a reduction in both
FRS and VAI when liraglutide is added to met-
formin compared to SE, regardless of duration
of disease and other clinical and biochemical
parameters.
Liraglutide is known to be effective in
reducing common CV risk factors [7–9]. In
addition, the effectiveness of liraglutide in
reducing leptin levels [10] and the VAI [11] has
recently been evaluated. In the last few years,
many studies have evaluated the capability of
the VAI to express the CM risk and a possible
adipose tissue dysfunction, in both the general
population and diabetic patients [12, 13].
To date, few studies have been mainly
directly aimed at comparing the extra-glycemic
effects of liraglutide in relation to previous and
concomitant hypoglycemic treatment, espe-
cially in the absence of modification of the
association therapy starting from diagnosis of
diabetes. In this study, although the individual
CV risk factors seemed to be improved in the
both groups, the FRS proved to be differently
influenced by the two treatments, indicating a
different role on CV played by liraglutide added
to metformin or to SE. Due to the different
behaviors of the parameters that affect FRS and
VAI, only FRS was significantly different
between the two groups at the end of follow-up,
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showing a reduction of above 40% in the group
A and a trend toward an increase, although not
significant, in group B. In agreement with these
data, it is widely demonstrated that the addition
of liraglutide to metformin proves effective in
improving several CV risk markers beyond gly-
cemic control [14]. In our patients, the addition
of liraglutide did not significantly change the
natural clinical course of patients who took SE,
while it significantly modified it when it was
added to metformin.
Confirming this datum, in our study the
concomitant hypoglycemic treatment was con-
firmed to be the only variable independently
and strongly associated with the FRS at multi-
variate analysis.
We could hypothesize that the beneficial
effect of liraglutide can be counterbalanced by
the effects of SE, whereas they are emphasized
by association with MET. These data are in
agreement with a previous large retrospective
observational study, which showed that the
probability of reaching good glycemic con-
trol was significantly higher in patients previ-
ously treated with metformin alone and
without any previous insulin, reinforcing the
hypothesis that better results with liraglu-
tide could be achieved in patients previously
treated with metformin [15].
The potential mechanism of these different
outcomes in the two groups is not fully clear,
although it has been widely demonstrated that
Fig. 1 Change in visceral adiposity index (a) and Framingham risk score (b) during liraglutide treatment in diabetic
patients grouped according to concomitant hypoglycemic therapy (blue line: metformin; orange line: insulin secretagogues)
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sulphonylurea and MET may differentially
affect the CV risk in diabetic patients [16–18]. A
hypothesis might be that sulphonylurea can
progressively cause b-cell failure by reducing the
efficacy of liraglutide [19].
It should be noted that the FRS is a tool for
CV risk assessment in the general population
with or without diabetes [6], so its application
in a diabetic population could potentially rep-
resent a bias. Indeed, in the FRS glycemic con-
trol and duration of diabetes are not included,
although these variables are important predic-
tors of CV risk. In this study, neither glycemic
control nor duration of disease may have played
a role, as they were similar in the two groups,
and the efficacy of liraglutide therapy in
reducing HbA1c levels was similar in the two
groups. Therefore, in this specific case the
change in FRS may be considered an extra-
glycemic effect of liraglutide. In addition, by
multivariate analysis we demonstrated that the
specific parameters of diabetes do not have any
significant influence on the outcome of the
study (FRS at 48 months and delta FRS from
baseline to 48 months). Of course, the diabetic
population of our study possesses a higher
well-recognized CV risk with respect to the
general population. However, the aim of this
study was not to cross-sectionally evaluate the
CV risk in the diabetic population, obviously
different from non-diabetic subjects, but to
observe the effect of two different hypoglycemic
treatments on longitudinal FRS modification.
A potential limitation of this study is the
small size of the sample of diabetic patients in
whom a priori power calculation was not per-
formed because of the retrospective nature of
the study. In this regard, we decided to rigor-
ously select patients according to unchanged
hypoglycemic treatment to have more reliable
results and avoid interference with the out-
comes of the study. Here, we show the results of
a smaller but homogeneous diabetic population
followed in a real-life setting, although certainly
our data need to be confirmed in a larger series
of patients.
In conclusion, our preliminary data extrac-
ted from real-life clinical practice suggest that
liraglutide as an add-on therapy to metformin
during a follow-up of 48 months is more
efficient in reducing the FRS compared with
addition to SE, regardless of the improvement
in glycemic control and VAI.
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